Intended for healthcare professionals

  1. Research
  2. Aspirin for primary...
  3. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
CCBYNC Open access
Research

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials

BMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b4531 (Published 06 November 2009) Cite this as: BMJ 2009;339:b4531

Data supplement

  • Web Extra

    Extra material supplied by the author

    Files in this Data Supplement:

Related articles

See more

Cited by...

  • A Bibliometric Analysis of Research Hotspots and Frontiers in Diabetes and Cardiovascular Disease Comorbidity from 2005 to 2024
  • 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes--2021
  • Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial
  • 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes--2020
  • 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes--2019
  • Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents
  • 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes--2018
  • Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
  • Response by Saito et al to Letter Regarding Article, "Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial"
  • Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial
  • 9. Cardiovascular Disease and Risk Management
  • Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus
  • Aborder les soins preventifs chez les aines
  • Approach to preventive care in the elderly
  • Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations
  • Cardiovascular Disease in Women: Clinical Perspectives
  • 8. Cardiovascular Disease and Risk Management
  • Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association
  • Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association
  • Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association
  • Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
  • Aspirin Therapy in Primary Cardiovascular Disease Prevention: A Position Paper of the European Society of Cardiology Working Group on Thrombosis
  • Author's reply to Cox and to McIntyre and colleagues
  • Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3)
  • Effects of Changing Guidelines on Prescribing Aspirin for Primary Prevention of Cardiovascular Events
  • Is diabetes a coronary artery disease equivalent?
  • Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register
  • Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention
  • High Glucose Inhibits the Aspirin-Induced Activation of the Nitric Oxide/cGMP/cGMP-Dependent Protein Kinase Pathway and Does Not Affect the Aspirin-Induced Inhibition of Thromboxane Synthesis in Human Platelets
  • Diabetic nephropathy
  • Platelet Isoprostane Overproduction in Diabetic Patients Treated With Aspirin
  • Is Reclassification of Intermediate-Risk Subjects by Coronary Artery Calcium Scoring Clinically Useful?
  • Differential Effect of Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Diabetes Management: A subanalysis of the JPAD trial
  • Individual and Population Benefits of Daily Aspirin Therapy: A Proposal for Personalizing National Guidelines
  • Antiplatelet Therapy for Every Diabetic Person?
  • Low-Dose Aspirin Therapy in Patients With Type 2 Diabetes and Reduced Glomerular Filtration Rate: Subanalysis from the JPAD trial
  • Type 2 diabetes and ASA
  • Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes
  • Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation
  • Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation
  • Meta-analysis: aspirin for patients with diabetes
  • Don't use aspirin for primary prevention of cardiovascular disease
  • Missing published and unpublished data in guidelines
  • BHS reaffirms its guidance
  • Time to rethink aspirin in diabetes?
  • Aspirin Unproved for Primary Prevention of CV Events in Patients with Diabetes
  • Aspirin for primary prevention of vascular disease in people with diabetes
Back to top